SS-31 Elamipretide
SS-31, known clinically as elamipretide, is a mitochondria-targeted peptide studied in heart failure and mitochondrial disease. Its clinical development is distinct from unsupported claims about general rejuvenation.
In September 2025, the US FDA granted accelerated approval to Forzinity, an elamipretide injection, for Barth syndrome in patients weighing at least 30 kg. Interest in its wider applications continues to grow.
What Is SS-31 Elamipretide?
Elamipretide is a synthetic tetrapeptide designed to act at the inner mitochondrial membrane. Mitochondria support cellular energy production and several other essential functions.
An approved pharmaceutical product is not interchangeable with a substance sold online under the SS-31 name. Product identity, quality and regulatory status matter.
How Does SS-31 Elamipretide Work?
Elamipretide interacts with cardiolipin, a lipid important to the inner mitochondrial membrane. This interaction is intended to support mitochondrial structure and function.
Effects on mitochondrial biology have made it a focus of research into energy and healthy ageing.
What Has Research Studied?
Clinical trials have investigated heart failure, primary mitochondrial disorders and Barth syndrome. Findings differ across populations, and studies have not consistently established benefit on their main endpoints.
The US accelerated approval for Barth syndrome was based on a measure considered reasonably likely to predict clinical benefit. Continued approval may depend on confirmation of benefit; it is not a general heart-failure or longevity approval.
Safety and Medical Supervision
Injection-site reactions and allergic reactions are relevant safety considerations. The approved product's current prescribing information should guide specialist assessment and monitoring.
A physician confirms the indication and suitability for each individual patient.
Frequently Asked Questions
Is elamipretide an approved medicine?
The US FDA granted accelerated approval to Forzinity for Barth syndrome in patients weighing at least 30 kg in September 2025. Wider research interest continues to grow.
Is SS-31 approved for longevity?
Longevity applications are an active research focus beyond the disease-specific approval.
Do heart-failure trials establish routine use?
Trial participation and a plausible mitochondrial mechanism have prompted ongoing research into heart failure applications.
Are online SS-31 products equivalent to Forzinity?
No equivalence should be assumed. Unregulated products may differ in identity, purity, formulation and manufacturing controls.
References
- US Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome
- PubMed. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Wondering Whether SS-31 Elamipretide Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.